Perspective Therapeutics (CATX) Operating Expenses (2010 - 2026)

Perspective Therapeutics has disclosed Operating Expenses across 17 years of filings, most recently posting $28.4 million for Q1 2026.

• Operating Expenses for Q1 2026 came in at $28.4 million, up 27.88% year-over-year; the trailing twelve-month figure through Mar 2026 was $120.6 million (up 19.22% YoY), and the FY2025 annual result was $114.4 million, up 23.94% from the prior year.
• Operating Expenses came in at $28.4 million for Q1 2026 at Perspective Therapeutics, down from $39.9 million in the prior quarter.
• In the past five years, Operating Expenses ranged from a high of $45.2 million in Q4 2024 to a low of $2.8 million in Q1 2022.
• The 5-year median for Operating Expenses is $13.3 million (2024), against an average of $17.3 million.
• Across the five-year window, Operating Expenses jumped 276.41% in 2024 and decreased 11.82% in 2025, its largest moves.
• Perspective Therapeutics' Operating Expenses stood at $5.6 million in 2022, then surged by 113.72% to $12.0 million in 2023, then surged by 276.41% to $45.2 million in 2024, then fell by 11.82% to $39.9 million in 2025, then slipped by 28.89% to $28.4 million in 2026.
• The last three Operating Expenses figures came in at $28.4 million (Q1 2026), $39.9 million (Q4 2025), and $28.1 million (Q3 2025), per Business Quant data.